

Russell Barrett Van Dyke, M.D.**Curriculum Vitae****Address:**

Office: Department of Pediatrics, TB-8
 Tulane University Health Sciences Center
 1440 Canal Street, Rm. 1600
 New Orleans, LA 70112
 Phone: 504-988-2570
 Fax: 504-988-3805
 Email: vandyke@tulane.edu

Home: 235 Lavergne Street
 New Orleans, LA 70114
 504-227-8249

Personal:

Birth: March 14, 1950; Pasadena, California
 Marital Status: Married. Nadiene Lynn Horst Van Dyke
 Children: Daryl Kloss Van Dyke
 Elizabeth Grace Van Dyke

Education:

1967-1971 B.A., Stanford University, Stanford, California
 1971-1975 M.D., Medical College of Wisconsin, Milwaukee, Wisconsin.

Post-Graduate Training:

1975-1976 Pediatric Internship, University of California, San Diego
 San Diego, California.
 1976-1978 Pediatric Residency, University of California, San Diego
 San Diego, California.
 1978 Chief Resident in Pediatrics, University of California, San Diego
 San Diego, California.
 1979-1980 Ophthalmology Residency, Stanford University
 Stanford, California.
 1980-1983 Fellowship in Pediatric Infectious Diseases
 University of California, San Diego, San Diego, California.
 Laboratory of Dr. James Connor

Certification:

1983 Pediatrics, American Board of Pediatrics
 [Certification No. 28947]
 1994 - 2015 Pediatric Infectious Diseases, American Board of Pediatrics, Subboard of Pediatric
 Infectious Diseases [Certification No. 466]

Medical Licensure:

1975 - 2002 California [No. G33094]
 1983 - present Louisiana [No. 6179R]

March 10, 2010

Academic Appointments:

1979	Assistant Clinical Professor of Pediatrics University of California, San Diego San Diego, California.
1983 - 1988	Assistant Professor of Pediatrics Section of Infectious Diseases Tulane University School of Medicine New Orleans, Louisiana.
1988 - 1990	Associate Professor of Clinical Pediatrics Acting Head, Section of Pediatric Infectious Diseases Tulane University School of Medicine
1990 - 1995	Associate Professor of Clinical Pediatrics Head, Section of Pediatric Infectious Diseases Tulane University School of Medicine
1995 - present	Professor of Clinical Pediatrics Head, Section of Pediatric Infectious Diseases Tulane University School of Medicine

Hospital Affiliations

1983 - present	Children's Hospital of New Orleans New Orleans, Louisiana.
1983 - 1994	Director of Infectious Diseases Infection Control Officer Clinical Director, Microbiology Laboratory Children's Hospital of New Orleans
1983 - present	Tulane University Medical Center New Orleans, Louisiana
1990 - present	Director of Infectious Diseases Tulane Hospital for Children
1983 – present	Medical Center of Louisiana New Orleans, LA
1990 - 2005	Director of Pediatric Infectious Diseases Unit Medical Center of Louisiana
1995- 2007	Ochsner Hospital New Orleans, LA
1997- present	Women's Hospital Baton Rouge, LA
2005 - present	West Jefferson General Hospital Jefferson, Louisiana.

Research Interests

March 10, 2010

Antiviral chemotherapy and antiviral sensitivity testing.
 Rapid viral diagnosis.
 Immunologic response to respiratory syncytial virus infection.
 The development of human monoclonal antibodies to respiratory syncytial virus and their use in prevention and modification of infection.
 The epidemiology, diagnosis, prevention, and treatment of human immunodeficiency virus infections in children. The pathogenesis of the vertical transmission of HIV.
 The epidemiology and prevention of HTLV-1 and HTLV-II infections.

Grant Support – Federal, State, and Foundations

"Rapid Diagnosis of Respiratory Syncytial Virus Infections"

American Heart Association, Louisiana Chapter.

Principal Investigator: Russell Van Dyke

July 1984 - June 1985

"Acyclovir Resistance of Varicella-Zoster Virus: Mechanisms and Development of a Screening Test"

Biomedical Research Support Grant

Tulane University School of Medicine

October 1984 - September 1985

"AIDS Clinical Trials Unit"

NIH Contract #NO1-AI-72625

Principal Investigator: Newton Hyslop, MD

Investigator

July, 1988 - October, 1990

NIH-NIAID Collaborative Antiviral Study Group

Principal Investigator: Richard Whitley, M.D.

NIAID Contract #NO1-AI-30025

Agency: NIAID, NIH

Role: Investigator

Period: 1990 - present

"Studies of Non-AIDS Human Retroviruses in Endemic Areas"

Centers For Disease Control Cooperative Agreement # U50/CCU603479-01

Principal Investigator: Russell Van Dyke, MD

9/30/89 - 9/29/93

\$110,000 (first year total costs)

"Tulane-LSU AIDS Clinical Trials Unit Pediatric Component"

NIAID #3 U01 AI27674-05S1

Principal Investigator: Russell Van Dyke, MD

1990-1992

\$195,282 (first year total costs)

"Tulane-LSU Pediatric AIDS Clinical Trials Unit"

NIAID #1 U01 AI-32913-01

Principal Investigator: Russell Van Dyke, MD

1992-1997

\$1,381,920. (first year total costs)

"Emergency Assistance to Hospitals"

Pediatric AIDS Foundation

Principal Investigator: Russell Van Dyke, MD

1993

\$5,350. (first year total costs)

"Ariel Project for the Prevention of HIV Transmission from Mother to Infant"

March 10, 2010

Pediatric AIDS Foundation
 Site Principal Investigator: Russell Van Dyke, MD
 1993-1997
 \$142,318. (first year total costs)

Pediatric AIDS Foundation Student Intern Award Program
 Student Sponsor
 Summer, 1993
 \$2,000. (Total Costs Awarded)

Pediatric AIDS Foundation Student Intern Award Program
 Student Sponsor
 Summer, 1994
 \$2,000. (Total Costs Awarded)

"Emergency Assistance to Hospitals"
 Pediatric AIDS Foundation
 Principal Investigator: Russell Van Dyke, MD
 1995
 \$5,900. (first year total costs)

Pediatric AIDS Foundation Student Intern Award Program
 Student Sponsor
 Summer, 1995
 \$2,000. (Total Costs Awarded)

"Tulane-LSU Pediatric AIDS Clinical Trials Unit"
 Principal Investigator: Russell B. Van Dyke, M.D. (40% effort)
 Agency: National Institutes of Health U01 AI-32913
 Inclusive dates: 3/1/97 - 2/28/02
 Amount of Award, entire project: \$4,761,437
 Direct costs of entire project: \$3,455,618

"A pilot study of early, aggressive therapy of HIV-infected infants with ZDV, 3TC, and 1592U89 to assess the effect on viral load and immune function"
 Pediatric AIDS Foundation
 Site Principal Investigator: Russell Van Dyke
 1997-1999
 Estimated first year award: \$12,000 direct costs

Basic Needs Grant
 Children Affected by AIDS Foundation
 1/1/1998-12/31/1999
 \$10,000 direct costs

"Incentive funding for an adolescent program."
 Pediatric AIDS Clinical Trials Unit.
 Principal Investigator: Russell Van Dyke.
 Inclusive dates: 2/1/99 – 2/28/01
 Amount of Award, entire project: \$176,668

Pediatric AIDS Foundation Student Intern Award
 Student Sponsor: Russell Van Dyke
 Summer, 1999
 \$2,000. (Total Costs Awarded)

Basic Needs Grant
 Children Affected by AIDS Foundation
 1/1/1999-12/31/2000
 \$10,000 direct costs

Pediatric AIDS Foundation Student Intern Award
 Student Sponsor: Russell Van Dyke
 Summer, 2000
 \$2,000. (Total Costs Awarded)

"Mother Infant (Rapid Intervention at Delivery Project (MIRIAD))"
 Centers For Disease Control Cooperative Agreement U64/CCU 617734
 Principal Investigator: Robert Maupin, M.D.
 Role: co-investigator
 Inclusive dates: 9/30/99 – 12/30/05
 First year direct costs, Tulane subcontract: \$39,128

Basic Needs Grant
 Children Affected by AIDS Foundation
 1/1/2001-12/31/2001
 \$10,000 direct costs

"Emergency Assistance to Hospitals"
 Pediatric AIDS Foundation
 Principal Investigator: Russell Van Dyke, MD
 2001
 \$4139.60 (first year total costs)

"Emergency Assistance to Hospitals"
 Pediatric AIDS Foundation
 Principal Investigator: Russell Van Dyke, MD
 2002
 \$2,600 (first year total costs)

"Tulane-LSU Pediatric AIDS Clinical Trials Unit"
 Principal Investigator: Russell B. Van Dyke, M.D. (40% effort)
 Agency: National Institutes of Health, NIAID, U01 AI-32913-14
 Inclusive dates: 3/1/02 - 2/28/07
 Amount of Award, year 14 direct costs: \$634,528

"Emergency Assistance to Hospitals"
 Pediatric AIDS Foundation
 Principal Investigator: Russell Van Dyke, MD
 2003
 \$1,915 (first year total costs)

"Emergency Assistance Funds"
 Pediatric AIDS Foundation
 Principal Investigator: Russell Van Dyke, MD
 2006
 \$20,000 (first year total costs)
 Emergency funds for our pediatric HIV population following Hurricane Katrina.

"Coordinating Center for the Pediatric HIV/AIDS Cohort Study (PHACS)"
 Principal Investigator: Russell B. Van Dyke, M.D. (35% effort)
 Agency: NICHD, NIH U01 HD052104-01
 Inclusive dates: 9/30/05 – 7/31/10
 First year direct costs: \$828,316
 The goals of this project are (1) to determine the safety to the child of preventive antiretroviral therapy when used to prevent mother-to-child transmission of HIV and (2) to determine the impact of perinatal HIV infection on adolescents and pre-adolescents.

Tulane/LSU Pediatric HIV/AIDS Clinical Trials Network Unit
 Principal Investigator: Russell B. Van Dyke, M.D. (35% effort)
 Agency: NIAID, NIH 1U01 AI-69460-01
 Inclusive dates: 3/1/07 - 11/30/07

First year direct costs: \$328,885

This award represents transitional funding for an IMPAACT Clinical Research Site to allow subjects currently of PACTG clinical trials to complete the protocols.

Pediatric HIV/AIDS Cohort Study – SMARTT Protocol

Site Principal Investigator: Russell B. Van Dyke, M.D. (20% FTE)

Agency: NICHD (WESTAT) subcontract under U01 HD052102-3

First year direct costs: \$133,415

Dates: 9/30/06-7/31/10

The goal of the SMARTT protocol is to conduct longitudinal surveillance of a cohort of HIV-uninfected infants and children who were born to HIV-infected mothers in order to identify toxicities related to in utero/neonatal exposure to maternal antiretroviral therapy and/or maternal HIV infection.

Clinical Site for the NICHD Pediatric and Perinatal HIV Studies Network

Site PI: Russell Van Dyke, MD

Agency: NICHD (WESTAT) subcontract under Prime Contract #HHSN267200800001C (NO-1-DK-8-0001)

Dates: 12/1/07-11/30/12

First year direct costs: \$526,349

The goal of this collaborative group is to conduct clinical trials of antiretroviral therapy in HIV-infected pregnant women, infants and children.

Grant Support - Other

"A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy and Tolerance of Acyclovir Capsules in the Prevention of Primary Varicella Zoster Virus Infection in Immunocompromised Susceptible Children With Documented Exposure to Varicella Zoster Virus"

Burroughs Wellcome Co.

September 1983 - October 1985

"A Comparative Study of Parenteral Ampicillin/Sulbactam Versus Ceftriaxone in the Treatment of Acute Bacterial Meningitis in Infants and Children"

Pfizer Pharmaceuticals

1987 - 1989

"A Double-Blind Comparison of Small Particle Aerosol Administration of Ribavirin and Placebo in Infants and Children Hospitalized With Influenza Virus Infections"

Viratek, Inc.

December 1987 - 1989

"A Double-Blind Placebo-controlled Safety, Immunogenicity, and Efficacy Study Comparing Multiple Doses of Tetravalent Rhesus Rotavirus Vaccine with Serotype 1 Reassortant Rhesus Rotavirus Vaccine"

Wyeth-Ayerst

Site Investigator: Russell Van Dyke, MD

August, 1989 - 1992

"Phase 1 Trial of HA-1A Human Monoclonal Antibody in Pediatric Patients with Gram-Negative Sepsis"

Participating Investigator: Russell Van Dyke, MD

Centocor, Inc.

1991

"A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Monthly RespiGam (RSVIG-IV)

Infusions for Reduction of the Rate of RSV Hospitalization in Premature Infants and Infants with Bronchopulmonary Dysplasia"

Medimmune, Inc.

Site Principal Investigator: Russell Van Dyke, MD

1994-1995

"A Pivotal Phase III Study of MEDI-493, a humanized respiratory syncytial virus monoclonal antibody, for the prophylaxis of severe RSV disease in premature infants and infants with bronchopulmonary dysplasia"

MedImmune, Inc.

Site Principal Investigator: Russell Van Dyke, MD
1996-1997
Estimated award: \$60,000 direct costs

"CNA3006: A double-blind, randomized, multicenter trial to evaluate the safety and efficacy of the combination of 1592U89/zidovudine/lamivudine versus the combination of zidovudine/lamivudine in HIV-1 therapy-experienced pediatric patients"
Glaxo Wellcome, Inc.
Site Principal Investigator: Russell Van Dyke, MD
1997-1999
Estimated first year award: \$60,000 direct costs

"PROAB3004: A randomized, double-blind, placebo-controlled phase III study to evaluate the safety and efficacy of 141W94 plus current nucleoside therapy versus current nucleoside therapy alone in protease-naive HIV-infected children"
Glaxo Wellcome, Inc.
Site Principal Investigator: Russell Van Dyke
1997-1999
Estimated first year award: \$50,000 direct costs

"A Phase I/II open label, multi-center study of the pharmacokinetics, safety, tolerance, and activity of two dose levels of adefovir dipivoxil and nelfinavir when added to antiretroviral therapy for the treatment of HIV-infected pediatric patients."
Gilead Sciences
Site Principal Investigator: Russell Van Dyke
1997-1999
Estimated first year award: \$50,000 direct costs

"Itraconazole oral solution in the treatment of oropharyngeal candidiasis in immunocompromised pediatric oncology patients, bone marrow recipients, and HIV infected subjects".
Janssen Research Foundation
Site Principal Investigator: Russell Van Dyke
1999-2000
Estimated first year award: \$30,000 direct costs

"A multicenter, double blind, placebo controlled trial of pleconaril in the treatment of enteroviral meningitis in children and adolescents" and "A multicenter, double blind, placebo controlled trial of pleconaril in the treatment of enteroviral meningitis in adolescents and adults"
ViroPharma Incorporated
Site Principal Investigator: Russell Van Dyke
1999-2000
Estimated first year award: \$30,000 direct costs

"Linezolid IV/PO vs. Vancomycin IV for the Treatment of Resistant Gram-Positive Bacterial Infections in Children".
Pharmacia & Upjohn
Site Principal Investigator: Russell Van Dyke
2000-2002
First year award: \$30,000 direct costs

"A Pivotal Phase 3 Study of MEDI-524 (Numax™), an Enhanced Potency Humanized Respiratory Syncytial Virus Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children".
MedImmune, Inc.
Site Investigator: Russell Van Dyke
2004-2005

"An open-label, single-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children."
Galaxo Smith Kline
Site Investigator: Russell Van Dyke
2004-2005

Teaching

Attending in Pediatric Infectious Diseases, Tulane Medical Center and University Hospital.
 General pediatric attending, University Hospital.
 Participant in clinical pediatric conferences and grand rounds, Tulane Medical Center
 Lecturer, Medical Microbiology, Clinical Pharmacology, and Pediatrics, Tulane School of Medicine.
 Lecturer, Tropical Medicine, Tulane School of Public Health.

Honors and Awards

- 1974 Alpha Omega Alpha Medical Honor Society
 Medical College of Wisconsin.
- 1984 Albert L. Hyman Research Grant Award
 American Heart Association, Louisiana Affiliate.
- 1997 Recipient, Tulane Owl Club Teaching Award
- 1998 Recipient, Community Service Award, Family Advocacy, Care, and Education Services (FACES),
 New Orleans, LA
- 2005 Recipient, Charles C. Shepard Science Award, Prevention and Control, CDC, for the publication
 of "Rapid HIV-1 Testing During Labor (for the Mother-Infant Rapid Intervention at Delivery
 (MIRIAD) Study Group). Journal of American Medical Association 2004; 292: 219-223.
- 2007 Recipient, Tulane University Health Sciences Center and its Board of Governors award for
 leadership in research.
- 2007 Recipient, Tulane University Health Sciences Center and its Board of Governors award for
 distinction in research.

Professional Societies:

- 1983 American Society for Microbiology
- 1984 Pediatric Infectious Diseases Society
- 1984 Greater New Orleans Pediatric Society
- 1985 Southern Society for Pediatric Research
- 1986 Pan American Group for Rapid Viral Diagnosis
- 1986 Fellow, American Academy of Pediatrics
- 1988 Fellow, Pediatric Infectious Diseases Society
- 1989 The Society of Hospital Epidemiologists of America
- 1991 Section of Infectious Diseases, American Academy of Pediatrics
- 1991 Infectious Diseases Society of America
- 1992 Louisiana/Mississippi Infectious Diseases Society

Editorial Services

- 1982 - present Reviewer, Journal of Pediatrics
- 1989 - present Reviewer, American Journal of Diseases of Childhood
- 1994 - 1997 Editorial Board, Pediatric AIDS and HIV Infection
- 1994 - present Reviewer, Pediatrics
- 1994 - present Reviewer, Infection Control and Hospital Epidemiology
- 1995 - present Reviewer, Journal of Infectious Diseases
- 1998 –present Reviewer, New England Journal of Medicine
- 2008 –present Reviewer, AIDS Patient Care and STDs

Community Activities

2002 - 2009 Board Member, Ronald McDonald House Charities of New Orleans
 2000 – present Treasurer, Algiers Historical Society

Graduate Student Committees

1997-1999 Heather B. Jaspan. Member of Doctoral Committee, Interdisciplinary Program in Molecular and Cellular Biology. Tulane University.
 1999-2001 Sheila Thomas. Member of Doctoral Committee, Department of Health Systems Management, School of Public Health and Tropical Medicine, Tulane University.

Intramural Committees

1985-1994 Chair, Infection Control Committee
 Children's Hospital of New Orleans

1986-1989 Chair, Pharmacy and Therapeutics Committee
 Children's Hospital of New Orleans

1985-1988 Chair, Residency Review Committee
 Department of Pediatrics
 Tulane University School of Medicine

1987-2005 Pediatric Advisory Committee
 Charity Hospital of New Orleans

1987-1994 AIDS Advisory Committee
 Children's Hospital of New Orleans

1987-1990 Chair, Pediatrics Committee
 Tulane-LSU AIDS Treatment Evaluation Unit

1988 Chair, Data Safety Monitoring Committee
 "IV Antibiotic Therapy in Cystic Fibrosis: Home vs. Hospital"
 [MCH 220556]
 Tulane Section of Pediatric Pulmonary Medicine

1988 - present Member, Graduate Medical Education Committee
 Department of Pediatrics
 Tulane University School of Medicine

1988 - present Member, Infection Control Committee
 Tulane University Medical Center

1988 - 1998 Member, Bloodborne Infection Committee
 Tulane University

1991- 2004 Antibiotic Review Subcommittee
 Tulane University Medical Center

1994 Member, Department of Microbiology Review Committee
 Tulane University School of Medicine

1994-1997 Member, Search Committee
 Joseph Slemmons Copes Chair in Infectious Diseases Epidemiology
 Tulane School of Public Health and Tropical Medicine

1995	Chair, Strategic Planning Committee Center of Infectious Diseases Tulane University Medical Center
1995 – present	Member, Committee on Research Tulane University Department of Pediatrics
1995 - present	Member, Executive Committee Tulane University Department of Pediatrics
1996 - present	Chair, Infection Control Committee [Serve as Chair and Vice-Chair on alternate years] Tulane University Medical Center
1998 - 2005	Member, Antibiotic Subcommittee, Pharmacy and Therapeutics Committee Charity Hospital of New Orleans
2003 – 2005	Chair, Bloodborne Infections Sub-Committee [Serves as Chair and Vice-Chair on alternate years] Tulane University Hospital
2003 - present	Member, Executive Committee Center for Evidence-Based Global Health Tulane School of Public Health and Tropical Medicine
2007- 2008	Member, Strategic Focus in Research Committee Tulane University
2007- present	Member, Search Committee Chair of the Department of Biostatistics Tulane University School of Public Health and Tropical Medicine
2007-present	Member, MCLNO/VA Planning Committee Tulane University Health Sciences Center
2007 - 2008	Member, Tulane/LSU General Clinical Research Center Advisory Committee Tulane University Health Sciences Center
2007- present	Member, Search Committee Chair of the Department of Neurology Tulane University Health Sciences Center
2007- present	Member, Search Committee Chair of the Immunology Program Tulane University Health Sciences Center
2007- 2009	Member, Infectious Diseases Planning Task Force Tulane University Health Sciences Center
2008- present	Member, Tulane/LSU Clinical and Translational Research Center Advisory Committee Tulane University Health Sciences Center
2008- 2009	Member, Search Committee Chair of the Department of Tropical Medicine Tulane University School of Public Health and Tropical Medicine
2008- present	Member, Grievance Committee Tulane University School of Medicine
2008	Member, Grant Review Panel

LSUHSC/TULANE Clinical & Translational Research, Education, and Commercialization
Program Pilot Projects

- 2008 Member, Grant Review Panel
The Louisiana Vaccine Center and the South Louisiana Institute for Infectious Disease
Research Cooperative Pilot Research Grant Fund.
- 2008- present Associate Program Director
Tulane/LSU Clinical and Translational Research Center (CTRC)
Tulane University Health Sciences Center
- 2008- present Member, Steering Committee
Tulane University Center for Infectious Diseases
Tulane University Health Sciences Center

State and National Committees

- 1985 - 1986 Committee on Research and Treatment
Louisiana State AIDS Task Force
- 1987 - 1990 Program Planning Subcommittee
Metropolitan AIDS Advisory Committee
New Orleans AIDS Project
- 1987- 1991 Pediatrics Committee
AIDS Clinical Trials Group, NIAID, NIH
- 1992 - present Institutional Representative
Southern Society for Pediatric Research
- 1992-1993 Vice-Chair, Opportunistic Infections Committee
Pediatric AIDS Clinical Trials Group, NIAID, NIH
- 1992 - 2006 Member, Pharmacology Committee
Pediatric AIDS Clinical Trials Group, NIAID, NIH
- 1994-1997 Chair, Opportunistic Infections Committee
Pediatric AIDS Clinical Trials Group, NIAID, NIH
- 1994 -1999 Member, Executive Committee, Pediatric AIDS Clinical Trials Group, NIAID, NIH
- 1994-1996 Member, AIDS Clinical Drug Development Committee, Division of AIDS, NIAID, NIH
- 1994 Member, Special Review Committee, NICHD, NIH; "Adolescent Medicine HIV/AIDS
Research Network: Basic Science Group"
- 1994 - 1996 Member, Governor's Task Force on HIV, State of Louisiana
- 1995 - 2007 Task Force Leader, NPHRC/HRSA/NIH Working Group on Antiretroviral Therapy and
Medical Management of HIV-Infected Children.
- 1997 - 2001 Chair, Adherence to Therapy Sub-Committee, Pediatric AIDS Clinical Trials Group,
NIAID, NIH.
- 1998 Member, ad hoc review panel, FDA Orphan Products Grant Program, Food and Drug
Administration, USPHS

- 1998 - 2007 Working Group Member, the USPHS/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections in Persons Infected with HIV , NIAID, NIH.
- 1998 - 2001 Vice-Chair, Complications of HIV Research Agenda Committee, Pediatric AIDS Clinical Trials Group, NIAID, NIH.
- 1998 - 2006 Member, Perinatal Transmission Research Agenda Committee, Pediatric AIDS Clinical Trials Group, NIAID, NIH.
- 1998 - 2009 Member, Protocol Evaluation Subcommittee, Pediatric AIDS Clinical Trials Group, NIAID, NIH.
- 2000 - 2006 Member, Sub-board of Pediatric Infectious Diseases and Associate Member, The American Board of Pediatrics.
- 2001 - 2003 Chair, Perinatal Transmission Research Agenda Committee, Pediatric AIDS Clinical Trials Group, NIAID, NIH.
- 2001 - 2004 Member, Credentials Committee, Sub-board of Pediatric Infectious Diseases, the American Board of Pediatrics.
- 2002 Member, ad hoc review panel, FDA Orphan Products Grant Program, Food and Drug Administration, USPHS
- 2002 – 2006 Member, Executive Committee, Pediatric AIDS Clinical Trials Group, NIAID, NIH.
- 2002 – 2008 Member, Antimicrobial Drug Resistance Task Force, Office of Public Health, State of Louisiana
- 2002 – 2009 Member, Board of Directors, Ronald McDonald House of New Orleans.
- 2003 – present Chair, Pediatric Long-Term Study Group (PACTG 219c), Pediatric AIDS Clinical Trials Group, NIAID, NIH.
- 2004 - 2006 Chair, Sub-board of Infectious Diseases, The American Board of Pediatrics.
- 2005 – present Chair, Executive Committee, Pediatric HIV/AIDS Cohort Study, NICHD, NIH.
- 2005 – present Chair, Scientific Leadership Group, Pediatric HIV/AIDS Cohort Study (PHACS) , NICHD, NIH
- 2006 – present Member, Committee on Pediatric AIDS, American Academy of Pediatrics
- 2006 - present Member, Louisiana Commission on HIV, AIDS, and Hepatitis C, State of Louisiana.
- 2007- present Co-Chair, DHHS Panel on the Treatment of HIV-Infected Children
Office of AIDS Research Advisory Council, Office of AIDS Research, NIH.
- 2007 - present Chair, Working Group on Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children.
Centers for Disease Control and Prevention, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and the Pediatric Infectious Diseases Society.
- 2008 – 2009 Member, Consultation on Prevention of HIV Mother-to-Child Transmission in the United States. Center for Disease Control and Prevention, Atlanta, GA.
- 2008 - present Co-Chair, Complications of HIV Working Group, Pediatric HIV/AIDS Cohort Study (PHACS), NICHD, NIH.

- 2009 – present Member, Complications of HIV Committee
International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)
NIAID, NIH
- 2009 – present Member, FDA Antiviral Drugs Advisory Committee
FDA

BIBLIOGRAPHY

Peer Reviewed Publications:

1. Van Dyke RB, Connor JD, Wyborny C, Hintz M, Keeney RE. Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis. *American Journal of Medicine* 73 (1A): 172-175, 1982.
2. Straube RC, Thompson MA, Van Dyke RB, Wadell G, Connor JD, Wingard D, Spector SA. Adenovirus type 7b in a children's hospital. *Journal of Infectious Diseases* 147: 814-819, 1983.
3. Van Dyke RB, Spector SA. Transmission of herpes simplex virus type 1 to a newborn infant during endotracheal suctioning for meconium aspiration. *Pediatric Infectious Diseases* 3: 153-156, 1984.
4. Van Dyke RB, Connor JD. Uptake of (¹²⁵I) Iododeoxycytidine by herpes simplex virus infected cells: a rapid screening test for acyclovir resistance. *Journal of Infectious Diseases* 1985; 152: 1206-1211.
5. Van Dyke RB, Murphey-Corb M. Detection of respiratory syncytial virus in nasopharyngeal secretions by DNA-RNA hybridization. *Journal of Clinical Microbiology* 1989; 27: 1739-1743.
6. Barrios NJ, Kirkpatrick DV, Murciano A, Stine K, Van Dyke RB, Humberty JR. Successful treatment of disseminated Fusarium infection in an immunocompromised child. *American Journal of Pediatric Hematology and Oncology* 1990; 12: 319-324.
7. Van Dyke RB. Pediatric human immunodeficiency virus infection and the acquired immunodeficiency syndrome: a health care crisis of children and families. *AJDC* 1991; 145: 529-32.
8. Zenker PN, Rosenberg EM, Van Dyke RB, Rabalais GP, Daum RS. Successful medical treatment of presumed *Candida* endocarditis in critically ill infants. *Journal of Pediatrics* 1991; 119: 472-477.
9. Lertora JJJ, Rege AB, Lacour JT, Frencz N, George WJ, Van Dyke RB, Agrawal KC, Hyslop NE Jr. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. *Clinical Pharmacology and Therapeutics* 1991; 50: 442-449.
10. Romano JM, Kearns GL, Kaplan SL, Jacobs RF, Killian A, Bradley JS, Moss MM, Van Dyke R, Rodriguez W, Straube RC. Single-dose pharmacokinetics and safety of HA-1A, a human IgM anti-lipid-A monoclonal antibody, in pediatric patients with sepsis syndrome. *J Pediatr* 1993; 122: 974-81.
11. Van Dyke, R.B. Pediatric HIV Infection and AIDS: A Progress Report. *AJDC* 1993;147: 524-5.
12. Working Group on Antiretroviral Therapy* [*Van Dyke RB]. Antiretroviral therapy and medical management of the human immunodeficiency-infected child. *Pediatric Infect Dis J* 1993; 12: 513-22.
13. Van Dyke, R.B. Opportunistic infections in pediatric HIV disease. *Annals of the New York Academy of Sciences* 1993; 693: 158-165.
14. Longfellow L, Troxler S, Michael G, Beltrami JF, Dal Corso M, McFarland L, Van Dyke R. Clinical implications of HIV seroprevalence in childbearing women: the Louisiana experience. *J LA State Med. Society* 1993; 145: 92-99.
15. Ward RL and Bernstein DI for the US Rotavirus Vaccine Efficacy Group* [*Van Dyke RB]. Protection against rotavirus disease after natural rotavirus infection. *J Infect Dis* 1994; 169: 900-4.
16. Rodriguez WJ, Hall CB, Welliver R, Simoes EAF, Ryan ME, Stutman H, Johnson G, Van Dyke R, Groothuis JR, Arrobio J, Schnabel K. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: A double blind, multicenter, placebo-controlled trial. *J Pediatr* 1994; 125: 129-135.

17. Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, Bryson YJ, Dankner WM, Livingston R, Connor EM, and the Pediatric AIDS Clinical Trials Group* [Van Dyke RB]. A Controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. *N Engl J Med* 1994; 331: 1181-1187.
18. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, Van Dyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moyer J, Statton P, Balsley J, for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Results of AIDS clinical trials group protocol 076. *N Engl J Med* 1994; 331: 1173-1180.
19. Van Dyke RB. Opportunistic Infections In HIV-Infected Children. *Seminars in Pediatric Infectious Diseases* 1995; 6: 10-16.
20. Duliege A-M, Amos CI, Felton A, Biggar RJ, the International Registry of HIV-Exposed Twins *, and Goedert JJ [Van Dyke RB]. Birth order, delivery route, and concordance in the transmission of human immunodeficiency virus type 1 from mother to twins. *J Pediatr* 1995; 126: 625-32.
21. Bernstein DI, Glass RI, Rodgers G, Davidson EL, Sack DA, for the U.S. Rotavirus Vaccine Efficacy Group*. [Van Dyke RB]. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in U.S. children. *JAMA* 1995; 273: 1191-6 .
22. Robinson WR, Wiley D, Van Dyke R. Effect of successive single-gestation pregnancies on the course of maternal human immunodeficiency virus disease and perinatal transmission. *Infectious Diseases in Obstetrics and Gynecology* 1995; 2: 251-4.
23. Van Dyke RB, Heneine W, Perrin ME, Rudolph D, Starszak E, Woods T, Switzer W, Kaplan JE. Mother-to-child transmission of human T-lymphotropic virus type II. *Journal of Pediatrics* 1995; 127: 924-28.
24. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Hermann SA, McSherry GD, O'Sullivan MJ, Van Dyke RB, Jimenez E, Rouzioux C, Flynn PM, Sullivan J, for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. *New England Journal of Medicine* 1996; 335: 1621-9.
25. Estrada B, Silio M, Begue RE, Van Dyke RB. Unsuspected hepatosplenic involvement in patients hospitalized with cat-scratch disease. *Pediatric Infectious Diseases Journal* 1996; 15: 720-21.
26. Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, Jacobs R, Van Dyke R, Burchett S, Soong SJ, Lakeman A, Whitley R.. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. *Pediatr Infect Dis J* 1996; 15: 247-54
27. The Prevent Study Group * [Van Dyke RB]. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. *Pediatrics* 1997; 99: 93-99.
28. Cao Y, Krogstad P, Korber BT, Koup RA, Muldoon M, Macken C, Song J-L, Jin Z, Zhao J-Q, Clapp S, Chen ISY, Ho DD, Ammann AJ, and the ARIEL Project Investigators *. [Van Dyke RB]. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel project for the prevention of HIV transmission from mother to infant. *Nature Medicine* 1997; 3: 549-52.
29. Centers for Disease Control and Prevention. (R. Van Dyke member of Working Group). 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *MMWR* 1997; 46 (No. RR-12): 1-46.
30. Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, McKinney RE Jr, Nichols S, Mitchell WG, Yogev R, Hutcheon N, and the ACTG 240 Team. A randomized comparative trial of stavudine

- (D4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. *Pediatrics* 1998; 101: 214-220.
31. Mirochnick M, Capparelli E, Dankner W, Sperling RS, Van Dyke R, Spector S. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. *Antimicrobial Agents and Chemotherapy* 1998; 42: 808-12.
 32. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. (R. Van Dyke, member of Working Group) Guidelines for the use of antiretroviral agents in pediatric HIV infection. *MMWR* 1998; 47 (No. RR-4): 1-44.
 33. Hughes W, Dorenbaum A, Yogev R, Beauchamp B, Xu J, McNamara J, Moye J, Purdue L, van Dyke R, Rogers M, Sadler B. Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group. *Antimicrob Agents Chemother.* 1998; 42(6): 1315-8.
 34. The IMPact-RSV Study Group* [*Van Dyke RB]. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infections in high-risk infants. *Pediatrics* 1998; 102: 531-537.
 35. Working Group on Antiretroviral Therapy and Medical Management of Infants, Children, and Adolescents With HIV Infection *. (* R. Van Dyke, Task Force leader and member of Writing Committee.) Antiretroviral Therapy and Medical Management of Pediatric HIV Infection. *Pediatrics* 1998; 102 (part 2): 1005-1062.
 36. Sperling RS; Shapiro DE; McSherry GD; Britto P; Cunningham BE; Culnane M; Coombs RW; Scott G; Van Dyke RB; Shearer WT; Jimenez E; Diaz C; Harrison DD; Delfraissy JF. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. *AIDS.* 1998 Oct 1;12(14):1805-13.
 37. Van Dyke RB, Korber BT, Popek E, Macken C, Widmayer SM, Bardeguez A, Hanson IC, Wiznia A, Luzuriaga L, Viscarello RR, Wolinsky S, and the Ariel Core Investigators. The Ariel Project - A Prospective Cohort Study of Maternal-Child Transmission of Human Immunodeficiency Virus Type 1 in the Era of Maternal Antiretroviral Therapy. *Journal of Infectious Diseases* 1999; 179: 319-328.
 38. The International Perinatal HIV Group *. [*Van Dyke RB, member of Steering Committee]. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: A meta-analysis of 15 prospective cohort studies. *New Engl J Med* 1999; 340: 977-87.
 39. Kline MW, Blanchard S, Fletcher CV, Shenep JL, McKinney RE, Brundage RC, Culnane M, Van Dyke RB, Dankner WM, Kovacs A, McDowell JA, Hetherington S, for the AIDS Clinical Trials Group 330 Team. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. *Pediatrics* 1999; 103: e47.
 40. Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE Jr; Abrams EJ; Mofenson LM, and the PACTG 327 Protocol Team. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. *Pediatrics* 1999;103: e62.
 41. USPHS/IDSA Prevention of Opportunistic Infections Working Group*. (* RB Van Dyke member) 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. *Clinical Infectious Diseases* 2000; 30: S29-65. Also published in *MMWR* 1999; 48 (No. RR-10):1-82.
 42. Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, McFarland E, Cunningham C, Duliege AM, Francis D, Bryson Y, Burchett S, Spector SA, Frenkel LM, Starr S, Van Dyke R, Jimenez E. for the Pediatric AIDS Clinical Trials Group and Protocol 230 team. Lymphoproliferative Responses to Recombinant HIV-1 Envelope Antigens in Neonates and Infants Receiving GP 120 vaccines. *Journal of Infectious Diseases* 2000; 181(3): 890-6.

43. Kaplan JE, Masur, H, Holmes KK, Freedberg KA, Holtgrave D, Piscitelli SC, Van Dyke R, Watts H, and the US Public Health Service/ Infectious Diseases Society of America Prevention of Opportunistic Infections Working Group. An overview of the 1999 US Public Health Service/ Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. *Clinical Infectious Diseases* 2000; 30: S15-28.
44. Lambert JS, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, Whitehouse J, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H, van Dyke R, Maupin R, Silio M, Fowler MG. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. *AIDS* 2000; 14 (10):1389-99.
45. Sáez-Llorens X, Nelson RP, Emmanuel P, Wiznia A, Mitchell C, Church J, Sleasman J, Van Dyke R, Richardson CG, Cutrell A, Spreen W, Hetherington S, and the CNAA 3006 Study Team. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated HIV-1-infected children. *Pediatrics* 2001; 107: e4.
46. The International Perinatal HIV Group *. [Van Dyke RB, member of Steering Committee and Writing Committee]. Duration of ruptured membranes and vertical transmission of HIV- 1: A meta-analysis from 15 prospective cohort studies. *AIDS* 2001; 15: 357-368.
47. Acosta EP, Zorrilla C, Van Dyke R, Bardeguet A, Smith E, Hughes M, Huang S, Pitt J, Watts H, Mofenson L, and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. Pharmacokinetics of Saquinavir-SGC in HIV-Infected Pregnant Women. *HIV Clinical Trials* 2001; 2: 460-465.
48. Van Dyke RB, Lee S, Johnson GM, Wiznia W, Mohan K, Stanley K, Morse EK, Krogstad PA, and Nachman S. Reported Adherence as a Determinant of Response to Highly Active Antiretroviral Therapy in Children Who Have Human Immunodeficiency Virus Infection *Pediatrics* 2002; 109: e61.
49. Acosta EP, Bardeguet A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, Pompeo L, Stek AM, Pitt J, Watts DH, Smith E, Jimenez E, Mofenson L and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. Pharmacokinetics of Saquinavir Plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women. *Antimicrobial Agents and Chemotherapy* 2004; 48: 430-436.
50. Bulterys M, Jamieson DJ; O'Sullivan MJ, Cohen MH, MD; Maupin R; Nesheim S; Webber MP; Van Dyke R; Wiener J; Branson BM; and the Mother Infant Rapid Intervention At Delivery Study Group. Performance of Rapid HIV-1 Testing at Labor and Delivery: A Multicenter Intervention Study. *JAMA*. 2004; 292:219-223.
51. Schuval S, Van Dyke RB., Lindsey JC., Palumbo P., Mofenson LM., Oleske JM, Cervia J, Kovacs A, Dankner WN, Smith E, Nowak B, Ciupak G, Webb N, Eagle M, Smith D, Hennessey H, Goodman-Kerkau M and Levin MJ for the Pediatric AIDS Clinical Trials Group Protocol 219C Team. Hepatitis C prevalence in children with perinatal HIV-1 infection enrolled in long-term follow-up protocol Pediatric AIDS Clinical Trials Group 219C. *Arch Pediatr Adolesc Med*. 2004 Oct;158(10):1007-1013.
52. Jaspan HB, Robinson JE, Amedee AM, Van Dyke RB, and Garry RF. Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies. *Journal of Clinical Virology* 2004; 31: 190-197.
53. Mofenson LM, Oleske J, Serchuck S, Van Dyke R, Wilfert C. Treating Opportunistic Infections Among HIV-Exposed and Infected Children: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. *Clinical Infectious Diseases* 2005;40 (Suppl 1): S1-S84. Also *MMWR* 2004;53(No. RR-14): 1-92.
54. Schuval S., Lindsey JC, Stapleton JT, Van Dyke RB, Palumbo P, Mofenson LM, Oleske JM, Cervia J, Kovacs A, Dankner WN, Smith E, Nowak B, Ciupak G, Webb N, Eagle M, Smith D, Hennessey R, Goodman-Kerkau M, Klinzman D, Hess G, Zdunek D, and Levin MJ for the Pediatric AIDS Clinical Trials Group Protocol 1028S Team. GB Virus C Infection in Children with Perinatal HIV-1 Infection. *Pediatric Infectious Diseases Journal* 2005; 24: 417-422.

55. Brogly S, Williams P, Seage GR, Oleske JM, Van Dyke R, McIntosh K for the PACTG 219C Cohort. Antiretroviral treatment in pediatric HIV in the United States: From clinical trials to clinical practice. *JAMA* 2005; 293: 2213-20.
56. Moon TD, Nadimpalli A, Martin EB, Ortiz MA, and Van Dyke RB. Balance and gait abnormalities of a child with West Nile virus infection. *Pediatric Infectious Diseases Journal* 2005; 24: 568-570.
57. Brogly S, Williams P, Seage GR, Van Dyke R. *In utero* nucleoside reverse transcriptase exposure and cancer in HIV- uninfected children: an update from the Pediatric AIDS Clinical Trials Group 219 & 219C cohorts. [Letter] *J Acquir Immune Defic Syndr* April 2006; 41: 535-536.
58. Gona P, Van Dyke R, Williams PL, Dankner WM, Chernoff MC, Nachman SA, Seage GR. Incidence of Opportunistic and Other Infections in HIV-Infected Children in the HAART Era. *JAMA* July 2006; 296: 292-300.
59. Ylitalo N, Brogly s, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR for the PACTG Protocol 219c Team. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. *Arch Pediatr Adolesc Med* August 2006; 160: 778-787.
60. Bagatell SJ. Weimer SM. Van Dyke RB. Bracey SV. Neck pain. *Clinical Pediatrics*. April 2007 46(3):280-1.
61. Flynn P. Havens P. Brady M. Emmanuel P. Read J. Hoyt L. Henry-Reid L. Van Dyke R. Mofenson L. Male circumcision for prevention of HIV and other sexually transmitted diseases. *Pediatrics*, April 2007. 119:821-2.
62. Weimer SM. Van Dyke RB. Bracey SV. Diagnosis: paraspinal (retropharyngeal) abscess with cervical osteomyelitis. *Clinical Pediatrics*, April 2007. 46:281-2.
63. Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, Abzug MJ, Brady M, Jean-Philippe P, Hughes MD, Seage III GR. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected. *AIDS* May 2007; 21: 929–938. PMID: 17457086
64. Rath B, Donato J, Duggan AI Perrin K, Bronfin DR, Ratard R, Van Dyke R, Magnus M. Adverse Health Outcomes after Hurricane Katrina among Children and Adolescents with Chronic Conditions. *Journal of Health Care for the Poor and Underserved* May 2007; 18: 405–417.
65. Brogly SB, Watts DH, Ylitalo N, Franco EL, Seage GR, Oleske J, Eagle M, Van Dyke R. Reproductive health of adolescent girls perinatally infected with HIV. *American Journal of Public Health*, June 2007; 97: 1047-52. PMID: 17463385
66. Pahwa S, Muresan P, Sleasman, J, Fenton T, Moye J, Deveikis A, Wara D, Van Dyke R, and the PACTG 402 team. Phase I/II Trial of Intermittent Subcutaneous Interleukin-2 Administration in Pediatric Patients with Moderate Immune Suppression: Results of Pediatric AIDS Clinical Trials Study 402. *J Allergy Clin Immunol*. June 2007;119:1538-41. PMID: 17418382
67. Zorrilla CD. Van Dyke R. Bardeguet A. Acosta EP. Smith B. Hughes MD. Huang S. Watts DH. Heckman B. Jimenez E. McSherry G. Mofenson L. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. *Antimicrobial Agents & Chemotherapy*, June 2007; 51 :2208-10. PMID: 17420209
68. Patel K, Hernán M, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage III GR for the PACTG219/219C Study Team. Long-term Effectiveness of Highly Active Antiretroviral Therapy (HAART) on the Survival of Children and Adolescents infected with HIV-1. *Clinical Infectious Diseases* February 15 2008; 46:507–17. PMID: 18199042
69. Rath BA, Register KB, Wall J, Sokol DM, Van Dyke RB. Persistent *Bordetella bronchiseptica* pneumonia in an immunocompetent infant and genetic comparison of clinical isolates with kennel cough vaccine strains. *Clinical Infectious Diseases* Mar 15, 2008; 46: 905-8.

70. Williams PL, Van Dyke R, Eagle M, Smith D, Vincent C, Ciupak G, Oleske J, Seage III GR for the PACTG 219c Team. Association of Site-Specific and Participant-Specific Factors with Retention of Children in a Long-term Pediatric HIV Cohort Study. *American Journal of Epidemiology*, June 1, 2008; 167:1375-86. PMID: 18413359
71. Patel K, Hernán M, Williams P, Seeger J, McIntosh K, Van Dyke R, Seage III GR, for the IMPAACT 219/219C Study Team. Long-term Effects of Highly Active Antiretroviral Therapy on CD4+ Evolution among Children and Adolescents Infected with HIV: Five years and counting. *Clinical Infectious Diseases* June 1, 2008; 46: 1751-60. PMID: 18426371
72. Van Dyke RB, Wang L, and Williams PL for the PACTG 219C Team. Toxicities Associated with Dual Nucleoside Reverse Transcriptase Inhibitor Regimens in HIV-Infected Children. *Journal of Infectious Diseases*, December 1, 2008; 198: 1599-1603.
73. Nachman S, Chernoff M, Gona P, Van Dyke RB, Dankner W, Seage III GR, Oleske J, Williams P for the PACTG 219C Team. Incidence of Non-Infectious Conditions in Perinatally HIV-Infected Children and Adolescents in the HAART Era. *Arch Pediatr Adolesc Med*, Feb 2009; 163: 164-171.
74. Cressey TR, Van Dyke R, Jourdain G, Puthanakit T, Roongpisuthipong A, Achalapong J, Yuthavisuthi P, Prommas S, Chotivanich N, Maupin R, Smith E, Shapiro DE, and Mirochnick M for the IMPAACT P1032 Team. Early Postpartum Pharmacokinetics of Lopinavir Initiated Intrapartum in Thai Women. *Antimicrobial Agents and Chemotherapy*, May 2009, 53: 2189–2191.
75. Malik S, Vranken P, Silio M, Ratard R, and Van Dyke R. Prevalence of Community-Associated Methicillin-Resistant *Staphylococcus aureus* Colonization Outside the Health-Care Environment. *Epidemiology & Infection*. Sep 2009; 137(9):1237-41.
76. Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, Van Dyke RB. Declines in Mortality Rates and Changes in Causes of Death in HIV-1–Infected Children During the HAART Era. *J Acquir Immune Defic Syndr*, January 2010; 53: 86–94.
77. Brogly SB, DiMauro S, Van Dyke RB, Williams PL, Naini A, Libutti D, Choi J, Chung M, Gerschenson M. Transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children. Submitted, August, 2009.
78. Crain MJ, Chernoff MC, Oleske JM, Brogly SB, Malee KM, R Borum PR, Meyer WA, Mitchell WG, Moye JH, Ford-Chatterton HM, Van Dyke RB, and Seage GR. Possible mitochondrial dysfunction and its association with antiretroviral use in children perinatally infected with HIV. In press, *Journal of Infectious Diseases*. 44365R1
- 79.

Books, Chapters, Reviews, and Non Peer Reviewed Publications

1. Van Dyke RB, Connor JD. "Pertussis". In *Current Pediatric Therapy* 10. Gellis SS and Kagan BM. (Eds.) Philadelphia, W.B. Saunders, pp. 513-514, 1981.
2. Van Dyke RB, Connor JD. "Plague". In *Current Pediatric Therapy* 11. Gellis SS and Kagan BM. (Eds.) Philadelphia, W.B. Saunders, pp. 547-548, 1984.
3. Connor JD, Hintz M, Van Dyke R, McCormick JB, McIntosh K. "Ribavirin pharmacokinetics in children and adults during therapeutic trials". In *Clinical Applications of Ribavirin*. Smith RA, Knight V, Smith JAD. (Eds.) Orlando, Academic Press, pp. 107-124, 1984.
4. Van Dyke RB, Desky AB, Daum RS. "Infections of the eye and periorbital structures." In: Arnoff SC (Ed.): *Advances in Pediatric Infectious Diseases*, Vol. 3. Chicago, Year Book Medical Publishers, Inc., pp. 125-79, 1988.

5. Steele RW, Van Dyke RB, Stagno SB. Afebrile pneumonia syndrome of infancy. AAP Pediatric Update, Vol. 10, 1990.
6. Brady MT, Van Dyke RB. Involvement of the ear, sinuses, oropharynx, parotid, cervical lymph nodes, and eye". In: Management of HIV infection in infants and children. Yogev R, Connor E (Eds.) St. Louis, Mosby-Year Book , Inc, 1992.
7. Van Dyke RB. "Antiviral therapy of pulmonary infections." In: Pediatric Respiratory Disease, Diagnosis and Treatment. Hilman B, (Eds.) Saunders, 1993.
8. Ketchum D, Van Dyke RB. "Viral pneumonia". In: Pediatric Respiratory Disease, Diagnosis and Treatment. Hilman B (Ed). Saunders, 1993.
9. Sillio M, Van Dyke RB. Disorders of the Skin in HIV-Infected Children. In: Current Opinion in Dermatology, 2nd Ed. Dahl MV and Jynch PJ [Eds]. Current Science, 1995.
10. Van Dyke RB. "Antibiotics in trauma". In: Pediatric Trauma: Initial Care of the Injured Child. Arensman RM (Ed). New York, Raven Press, 1995.
11. Van Dyke RB. Management of bacterial infections in HIV-infected children. Opportunistic Complications of HIV 1996; 5: 49-53.
12. Van Dyke RB. Bacterial infections - another consideration in HIV immunosuppression. Opportunistic Complications of HIV 1996; 5: 37-38.
13. Baumgarten KL, Van Dyke RB, Dalovisio JR. Unusual skin lesions – New Orleans Citywide Rounds. Infections in Medicine 2000; 17: 88-91.
14. Van Dyke RB. Commentary. Pediatric Emergency and Critical Care 2000; 13: 31-32.
15. Van Dyke RB, McKinney RE Jr. "Pediatric immunodeficiency virus infections: Natural history, perinatal transmission, and opportunistic infections." In: Clinical Management of Infections in Immunocompromised Infants and Children. Patrick CC (Ed.) Lippincott Williams & Wilkins, 2001.
16. Perez Mato S, Van Dyke R. Pulmonary infections in children with HIV infection. Semin Respir Infect 2002 Mar;17(1):33-46
17. Ramgoolam A, Van Dyke RB. "Cholera" In: Gellis & Kagan's Current Pediatric Therapy 17. Burg FD, Ingelfinger JR, Polin RA, Gershon A, , (Eds.). pp. 60-62. WB Saunders Co, 2002.
18. McKinney RE Jr and Van Dyke RB,. "Paediatric HIV." In: Management of the HIV-Infected Patient. Crowe S, Hoy J, and Mills J. (Eds.) Martin Dunitz, 2002.
19. Abrams E, Moon RY, Robinson L-G, and Van Dyke RB. "Routine Pediatric Care." In: Handbook of Pediatric HIV Care. Zeichner SL and Read JS (Eds.) Cambridge University Press, 2006.
20. Read JS and the American Academy of Pediatrics Committee on Pediatric AIDS* [Van Dyke RB, member]. Diagnosis of HIV-1 Infection in Children Younger Than 18 Months in the United States. Pediatrics 2007; 120: e1547- e1562.
21. Flynn P, Havens P, Brady M, Emmanuel P, Read J, Hoyt L, Henry-Reid L, Van Dyke R, Mofenson L, Male Circumcision for Prevention of HIV and Other Sexually Transmitted Diseases. [Commentary] Pediatrics, Apr 2007; 119: 821 - 822.
22. Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, Havens P, Nesheim S, Read J, Serchuck L, and Van Dyke RB. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of

Pediatrics. Morbidity & Mortality Weekly Report. Recommendations & Reports Sep 4, 2009; 58(RR-11): 1-166.

Abstracts:

1. Straube RC, Van Dyke RB, Spector S, Connor JD, Chadwick D. A nosocomial outbreak of fatal adenovirus type 7. *Pediatric Research* 15: 523, 1981.
2. Van Dyke RB, Hintz M, Wyborny C, Connor JD, Spector S, Creagh-Kirk T, Keeney R. Oral acyclovir pharmacokinetics in patients with herpes proenitalis. International Acyclovir Symposium, Bethesda, Maryland, September 1981.
3. Van Dyke R, Straube R, Large K, Hintz M, Spector S, Connor JD. Pharmacokinetics of increased dose acyclovir. Proceedings of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, October, 1982.
4. Hintz M, Connor JD. Pharmacology of ribavirin aerosol therapy in children. Proceedings of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, October, 1982.
5. Van Dyke RB, Connor JD. Uptake of 5-¹²⁵I-labeled deoxycytidine by herpes simplex virus-infected cells as a screen for acyclovir resistance. Proceedings of the 23rd Interscience conference on Antimicrobial Agents and Chemotherapy, Las Vegas, October, 1983.
6. Hintz M, Yeager A, Connor JD, Spector SA, DeVinney R, Van Dyke R. Acyclovir pharmacokinetics in neonates with herpes simplex virus infections. Proceedings of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, October, 1983.
7. Connor JD, Van Dyke R, Hintz M, De Vinney R, McIntosh K. Pharmacokinetics of ribavirin small-particle aerosol therapy in children and adults. Proceedings of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, October, 1983.
8. Connor JD, Hintz M, Van Dyke R, McCormick J, McIntosh K. Ribavirin pharmacokinetics in children and adults during therapeutic trials. Second Symposium on Viral Chemotherapy. Newport Beach, California, September 1983.
9. Van Dyke RB, Murphey-Corb M. Nucleic acid hybridization for the detection of respiratory syncytial virus. International Symposium in the Biomedical Sciences: Clinical Virology. Clearwater Beach, Florida, April 1985.
10. Van Dyke RB, Murphey-Corb M. Detection of respiratory syncytial virus by nucleic acid hybridization. *Clinical Research* 34: 251A, 1986.
11. Lopez K, Van Dyke RB. Risk factors for the development of infection after placement of a spinal rod in children. Proceedings of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September, 1986.
12. Van Dyke RB. Detection of respiratory syncytial virus in clinical samples by nucleic acid hybridization. Proceedings of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September, 1986.
13. Van Dyke RB, Robinson J. Production of human monoclonal antibodies to respiratory syncytial virus. Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October, 1988.
14. Lertora JLL, Rege AB, Ferencz N, Lacour JT, Jeffers T, George WJ, Van Dyke RB, Agrawal KC, and Hyslop NE. Pharmacokinetics of ribavirin in asymptomatic HIV-infected patients. Sixth AIDS Clinical Trials Group Meeting, Washington D.C., July, 1989.

15. Christina M, Alchediac T, Redlin C, McFarland L, Muirhead L, and RB Van Dyke. Infants born to HIV-Infected women identified in a prenatal screening program: A preliminary report. *Clinical Research* 1990; 38: 54A
16. Van Dyke RB, Alchediak T, Redlin CM, Lefebvre AR, Sood SK. Immunogenicity of haemophilus influenzae B conjugate vaccine in infants born to HIV-infected women. Eighth AIDS Clinical Trials Group Meeting, Washington D.C., March, 1990.
17. Humbert JR, Winsor EL, Curnutte JT, Van Dyke RB, Sood SK, Zembo MA. Resolution of Aspergillus osteomyelitis in chronic granulomatous disease with interferon gamma and itraconazole. [Abst. # 1024] *Pediatric Research* 1990; 27 (4): 173A.
18. Van Dyke RB, Alchediac T, Redlin CM, Lefebvre AR, Sood SK. Immunogenicity of haemophilus influenzae B conjugate vaccine in infants born to HIV-infected women. [Abst. # 1094] *Pediatric Research* 1990; 27 (4): 185A.
19. Van Dyke R, Calligaro D, Africk D, Redlin C, Alchediak T.: Follow-up of infants born to HIV-infected women identified in a prenatal screening program. Sixth International Conference on AIDS, San Francisco, California, June 1990.
20. Humbert JR, Winsor EL, Van Dyke RB. Improvement in neutrophil function following interferon therapy in a patient with chronic granulomatous disease. *Clinical Research* 1990; 38: 997A.
21. Gomez L, Van Dyke RB, Alchediak T, and Stine KC. CD4 and CD8 Lymphocyte profiles in uninfected infants born to HIV-1 infected mothers. [Abst. # 923] *Pediatric Research* 1991; 29 (4, pt. 2): 156A.
22. Van Dyke RB, Calligaro D, Gomez L, Alchediak T, Stine KS. CD4 and CD8 lymphocyte profiles in HIV-seronegative uninfected infants born to HIV-1 infected mothers. Eleventh AIDS Clinical Trials Group Meeting, Washington D.C., March, 1991.
23. Ketchum DG, Van Dyke RB. Rapid screening of clinical herpes simplex virus isolates for resistance to acyclovir. Fourth International Conference on Antiviral Research, New Orleans, Louisiana, April 23, 1991.
24. Lertora J, Rege A, Lacour J, Ferencz N, George W, Agrawal K, Van Dyke R, Hyslop N. Ribavirin pharmacokinetics and tolerance in HIV-infected patients. Abstract #W.B.2077. VII International Conference on AIDS, Florence, Italy, June 19-20, 1991.
25. Ada N, Quintana L, Mera R, Lopez C, Van Dyke RB. One-year historic prospective series of central venous cathete infections in a children's hospital. *Clinical Research* 1991; 39: 842A.
26. Clark R, Dumestre J, Pindaro C, Abadie M, Brandon W, Wisniewski T, O'Connor S, Van Dyke R, Hyslop N. Evaluation of a model for health care delivery to HIV positive women in New Orleans. Fourteenth AIDS Clinical Trials Group Meeting, Washington D.C., March, 1992.
27. Morse E, Simon P, Abadie M, Van Dyke R. Identification of barriers to patient compliance on protocol #076. Fourteenth AIDS Clinical Trials Group Meeting, Washington D.C., March, 1992.
28. Van Dyke RB, Perrin M, Roberts B, Starszak E, Green D, Heneine, Kaplan JE. HTLV-I and HTLV-II infection among pregnant women attending a large public hospital in New Orleans. Abstract # PoC 4393, VIII International Conference on AIDS, Amsterdam, Holland, 1992.
29. Rodriguez WJ, Hall CB, Welliver R, Simoes EAF, and the Influenza Study Group* [Van Dyke RB]. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double blind, placebo-controlled trial. Presented at the Society for Pediatric Research, 1992.
30. Kearns G, Romano M, Kaplan S, Jacobs R, Killean A, Bradley J, Moss M, Van Dyke R, Rodriguez W. Single-dose pharmacokinetics of HA-1A in pediatric patients with sepsis syndrome. Abstract #1237. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 1992.

31. Van Dyke RB, Starszak E, Robinson JE. A simple enzyme immunoassay for the discrimination between infection with HTLV-I and HTLV-II. Abstract #1350. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 1992.
32. Kaplan J, Shaffer N, Van Dyke R, Abrams E, Krasinski K, Perrin M, Roberts B, Heneine W. Lack of mother-to-child transmission of HTLV-II in non-breast-fed infants. Abstract #1725. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 1992.
33. Wiley D, Abadie M, Van Dyke R, Gaumer R, Robinson W. The effect of multiple single gestatin pregnancies on the course of HIV disease in mothers. Abstract # PO-B23-1933. IX International Conference on AIDS, Berlin, Germany, 1993.
34. Aliabadi-Wahle S, Perrin M, Williams T, Van Dyke R. Vertical Transmission of HIV in a Cohort of Infants Born to HIV-Infected Women Identified in a Prenatal Screening Program. Abstract #674, "The First National Conference on Human Retroviruses and Related Infections", Washington, DC, December 1993.
35. Simon P, Morse E, Perrin M, Van Dyke R. Utility of an Observational Data Base for Women Referred to ACTG #076. 17th AIDS Clinical Trials Group Meeting, Washington, DC, December 1993.
36. Van Dyke R, Mera R, Bitar C, Gaumer R. Use of Immunophenotypic Data for Discrimination of Infected and Uninfected Children in the First Year of Life. 17th AIDS Clinical Trials Group Meeting, Washington, DC, December 1993.
37. Price J, Miller M, Mera R, Morse E, Simon P, Prosper T, Leyva G, Van Dyke R. Critical Effect of Nursing Continuity on Management of HIV-Infected Pediatric Study Participants. Division of AIDS, NIAID, 18th AIDS Clinical Trials Group Meeting, Washington, DC, December 1993.
38. Morse E, Simon P, Perrin M, Spalitta G, Degenstein C, Anglin S, Butler O, Van Dyke R. Interpersonal and Individual Factors Affecting Female Patient Compliance. 17th AIDS Clinical Trials Group Meeting, Washington, DC, December 1993.
39. Van Dyke RB, Heneine W, Perrin M, Rudolph D, Starszak E, Woods T, Switzer W, Kaplan J. Vertical transmission of HTLV-II in the presence and absence of breast feeding. Abstract #E10. The Sixth International Conference on Human Retrovirology: HTLV. AIDS Research and Human Retroviruses 1994; 10:483.
40. Diaz C, Yogev R, Hawkins E, Rogers A, Culnane M, Carrer M, Van Dyke R, Hetherington S, Cooper E, Scott W, Fenton T. ACTG 153: A multicenter phase 1, dose escalating study of interferon-alpha in children with early HIV disease progression. Abstract #3169: Xth International Conference on AIDS, Yokohama, Japan, 1994.
41. Diaz C, Yogev R, Culnane M, Rogers A, Hawkins P, Van Dyke R, Hetherington S, Fenton T, and the AIDS Clinical Trials Group. ACTG 153: a multicenter phase 1 study of alfa interferon in HIV-infected children. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, Oct., 1994.
42. Hatten T, Michael G, Farley T, Mera R, Van Dyke R. Prenatal HIV screening: Potential impact on pediatric HIV infections. Journal of Investigative Medicine 1995; 43: 38A.
43. Silio MB, Sokol DS, Van Dyke RB, Bitar CN, Alchediak T, Pramberg JC. Growth Failure as an Early Clinical Marker of Disease Progression in Pediatric HIV Infection. Journal of Investigative Medicine. 43:15A, Feb. 1995.
44. Morse E, Simon P, Kaplan L, Perrin M, Price J, Miller M, Mera R, Van Dyke R. Predicting medication compliance of women participating in ACTG protocol #076. 19th AIDS Clinical Trials Group Meeting, Washington, DC, February, 1995.
45. Van Dyke RB, Hatten T, Michael G, Mera R, Farley TA. Importance of prenatal HIV testing in the prevention of pediatric HIV infection [Abst. # 681]. Pediatric Research 1995; 37 (#4, pt. 2): 116A.

46. Van Dyke RB, Yogev R, Cervia J, Lertora JJ, George WJ and ACTG #189 team. Pharmacokinetics and tolerance of intravenous pentamidine in HIV-infected children. Abstract #A18, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Sept., 1995.
47. Koup RA, Cao Y, Ho DD, Krogstad PA, Chen IS, Korber BTM, Wolinsky SM, Mullins J, Walker B, Ammann A, and the Ariel Project Cohort Group *. [* Van Dyke RB] Lack of a maternal viral threshold for vertical transmission of HIV-1. Abstract #LB2, Third Conference on Retroviruses and Opportunistic Infections, Washington, D.C, Jan. 28-Feb. 1, 1996.
48. Van Dyke RB, Amedee A, Sokol D, Holton D, Perrin M, Bienvenu S, McBride E, Murphey-Corb M. Comparison of V3 loop sequences of maternal and infant-derived HIV strains. Abstract #2977, the XIth International Conference on AIDS, Vancouver, Canada, July 10, 1996.
49. Van Dyke R, Korber B, Bardeguez A, Gorenssek M, Hanson C, Luzuriaga K, Viscarello R, Wiznea A, Koup R, Ammann A, and the ARIEL Project Core Researchers. Factors in Addition to Viral Load Influence Maternal- Child Transmission of HIV. Abstract #116, 34th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Sept. 18-20, 1996.
50. Kline MW, Lindsey JC, Culnane M, Van Dyke RB, and the ACTG group 240 team. A randomized comparative trial of zidovudine versus stavudine in children with HIV infection. Abstract #724. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997; Washington, D.C.
51. Dorenbaum A, Sadler BM, Xu J, Van Dyke RB, Wei LJ, Moye J, McNamara J, Yogev R, Diaz C, Hughes W for the Pediatric ACTG and Glaxo Wellcome Inc. Phase I safety and pharmacokinetics study of micronized atovaquone in HIV exposed or infected infants and children. Abstract #288. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997; Washington, D.C.
52. Popek EJ, Korber BT, Merrett L, Bardenguez A, Lee A, Hammill HA, Wiznia A, Viscarello R, Luzuriaga K, and Van Dyke RB. Acute chorioamnionitis and duration of membrane rupture correlates with vertical transmission of HIV-1. Abstract #504. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997; Washington, D.C.
53. Estrada B, Goebel J, Boerth RC, Van Dyke RB. Streptococcus pneumoniae associated hemolytic uremic syndrome: two cases from Mobile, AL. Journal of Investigative Medicine 1997; 45: 13A.
54. Estrada B, Patnaik M, Van Dyke RB, Begue RE, Sokol D. High seroprevalence of Bartonella henselae antibodies in HIV infected children. Journal of Investigative Medicine 1997; 45: 36A.
55. Kline MW, Blanchard S, Shenep JL, McKinney RE Jr., Van Dyke RB, Culnane M, Danehower S, Lanier ER, Hetherington S, and the AIDS Clinical Trials Group 330 Team. A phase 1 study of 1592U89 in HIV-infected children. Abstract #269. 5th Conference on Retroviruses and Opportunistic Infections, Feb. 1-5, 1998; Chicago, IL.
56. Reed J for the International Perinatal HIV Group*. (*Van Dyke RB) Mode of delivery and vertical transmission of HIV-1: A meta-analysis from fifteen prospective cohort studies. Abstract #23275. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
57. Van Dyke R, Saez-Llorans X, Nelson RP, Emmanuel P, Wiznia A, Gilbert CA, Keller A, and the CNA 3006 Study Group. Antiretroviral activity and safety of abacavir/3TC/ZDV in therapy-experienced children. Abstract #128/12255. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
58. Scott G, Oleske J, Grubman S, Mofenson L.M., Burr C., Van Dyke R., Dashefsky B. Antiretroviral therapy and medical management guidelines of pediatric HIV infection. Abstract #32439. Presented at the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
59. Van Dyke R, G. McSherry, C. Diaz, V. Bonagurra, A. Wiznia, K. McIntosh, S. Rana, M. Rathore, M. Kang, T Fenton, and the PACTG #274 Study team. A Phase-1 Dose-Escalating Study of the

Combination of Didanosine Plus Ribavirin in HIV-Infected Children. Abstract #13-I-6, 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, Sept. 24-27, 1998.

60. Wiznia A, Nelson R, Van Dyke R, Bakshi S, Cundy K, Dawson K, Kosloff A, Esinhart J, Coakley D. Phase I/II study of combination of adefovir dipivoxil and nelfinavir in children with HIV infection and previous antiretroviral experience. Abstract #13-I-9, 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, Sept., 1998.
61. Lertora JLL, Harrison M, Dreisbach AW, Van Dyke RB for the PACTG #274 Study Team. Lack of pharmacokinetic interaction between ddI and ribavirin in HIV-infected children. *Journal of Investigative Medicine* 1999; 47 #2: 106A.
62. Van Dyke RB, Lee S, Stanley K, Johnson GM, Morse EV, PACTG Adherence Subcommittee and PACTG 377 Team. Reported Adherence as a Determinant of Response to Highly Active Antiretroviral Therapy (HAART) in HIV-Infected Children. Abstract #1647. Society for Pediatric Research, Boston, MA, May 12, 2000.
63. Xavier Saez-Llorens, Robert P. Nelson, Jr., Patricia Emmanuel, Andrew Wiznia, Joseph Church, John Sleasman, Russell Van Dyke, Carol G. Richardson, Christine Rosko, Amy Cutrell, Seth V. Hetherington. Ziagen (Abacavir, ABC) Combined with 3TC & ZDV is Safe and Effective Through 48 Weeks in HIV-1 Infected Antiretroviral Therapy-Experienced Children. Abstract #1623. Society for Pediatric Research, Boston, MA, May 12, 2000.
64. Acosta EP, Zorrina C, Van Dyke RB, Bardeguet A, Smith B, Hughes M, Pitt J, Mofenson L, and the PACTG 386 protocol team. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. Presented at the 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April, 2001.
65. Pérez Mato S, Robinson J E, Amedee AM., and Van Dyke RB. Novel Inhibitory Factor(s) of Human Immunodeficiency Virus type 1 (HIV-1) in Amniotic Fluid and *In Utero* Transmission of HIV-1. Abstract #22, Presented at the 39th annual meeting of the Infectious Diseases Society of America, San Francisco, Oct. 25-28, 2001.
66. Acosta, E.P.; Zorrilla, C.D.; Bardeguet, A.; Van Dyke, R.; Smith, B.; Huang, S.; Pitt, J.; Watts, H.; Mofenson, L. Pharmacokinetics (PK) of Saquinavir/Ritonavir (SQV/RTV) in HIV-Infected Pregnant Women. Presented at the 42nd ICAAC Meeting. San Diego CA, Sept. 2002.
67. Zorrilla C. D., R. Van Dyke, A. Bardeguet, J. Pitt, E. Acosta, M. Hughes, S. Huang, B. Heckman, S. Ortiz-Pujols, B. Smith, H. Watts, and L. Mofenson. Clinical Response, Safety, and Tolerability to Saquinavir-SCG with Low-dose Ritonavir Boosting in Combination with Zidovudine and Lamivudine in HIV-1 Infected Pregnant Women: Preliminary Results of PACTG 386. Abstract #887. Presented at the 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003, Boston, MA.
68. Schuval S, Van Dyke R, Lindsey J, Hess G, Zdunek D, Klinzman D, Stapleton J. GB virus C prevalence in perinatally-infected HIV-positive children. Abstract #682, 41st Annual Meeting of the Infectious Diseases Society of America, October 9-12, 2003, San Diego, CA.
69. Schuval S, Van Dyke R, Lindsey J, Palumbo P, Levin M, Oleske J, Cervia J, and Mofenson L. Hepatitis C prevalence in perinatally-infected HIV-positive children. Abstract #683, 41st Annual Meeting of the Infectious Diseases Society of America, October 9-12, 2003, San Diego, CA.
70. Shapiro D, Muresan P, Mofenson L, Fowler MG, McSherry G, van Dyke R. Perinatal Zidovudine (AZT) Exposure in PACTG 076 and Long-Term Effect on Hematologic Parameters in HIV-Exposed but Uninfected Children. Abstract no. ThPeB7023 XV International AIDS Conference, July, 2004, Bangkok, Thailand.
71. M Bulterys, D J Jamieson, M J O'Sullivan, M H Cohen, R Maupin, S Nesheim, M P Webber, R Van Dyke, J Wiener, B M Branson. Rapid HIV-1 testing during labor: a multicenter interventional study in the United States. Abstract No. ThPeB7027. XV International AIDS Conference, July, 2004, Bangkok, Thailand.

72. Ylitaol N, Nachman S, Brogly S, VanDyke R, Hughes M, Seage G. Opportunistic Illnesses in the post HAART Era. XV International Conference on AIDS, Bangkok, Thailand, July 2004.
73. Van Dyke RB, Gona P, Dankner WM, Nachman SA, Williams PL, and Seage GR. Incidence of Opportunistic and Other Infections in HIV-Infected Children in the HAART Era. Abstract # 950. Presented at the 42nd Annual Meeting of the Infectious Diseases Society of America, September 30-October 3, 2004, Boston, MA.
74. Nachman SA, Gona P, Van Dyke RB, Dankner WM, Williams PL, and Seage GR. Incidence of non-infectious complications in perinatally HIV-infected Children and Adolescents in the HAART Era. Abstract #951. Presented at the 42nd Annual Meeting of the Infectious Diseases Society of America, September 30-October 3, 2004, Boston, MA.
75. Malik SM, Magnus M, Silio M, Van Dyke RB. Use of gastrostomy to Promote Adherence in HIV-Infected Children. Abstract #947. Presented at the 42nd Annual Meeting of the Infectious Diseases Society of America, September 30-October 3, 2004, Boston, MA.
76. Rath BA, Sokol DM, Wall JH, Van Dyke RB. *Bordetella bronchiseptica* Infection in Dogs, Cats and - Kids!. Abstract #276. Presented at the 42nd Annual Meeting of the Infectious Diseases Society of America, September 30-October 3, 2004, Boston, MA.
77. Van Dyke RB, Scott G, Cohen M, Nesheim S, Abrams E, Danner S, Bulterys M, and the MIRIAD Study group. The Outcome of Infants Born to HIV-Infected Women Identified by Rapid HIV Testing Late in Pregnancy or at Delivery: The MIRIAD Study, 2001-2004. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Feb. 22-25, 2005, Boston, MA.
78. Brogly S, Ylitalo N, Mofenson L, Oleske J, Van Dyke R, Crain M, Abzug M, Brady M, Jean-Philippe P, Hughes M, and Seage G. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children in the Pediatric AIDS Clinical Trials Group (PACTG) protocols 219 & 219C. Abstract no. THAB0103. XVI International AIDS Conference, August 13-18, 2006, Toronto, Canada.
79. Williams P, Wang L, and Van Dyke R for the PACTG 219C Study Team. Toxicity of combination NRTI regimens in treatment of pediatric HIV infection. Abstract no. WEPE0141, XVI International AIDS Conference, August 13-18, 2006, Toronto, Canada.
80. Cressey TR, Van Dyke R, Jourdain J, Puthanakit T, Roongpisuthipong A, Jullapong Achalapong J, Yuthavisuthi P, Prommas S, Chotivanich N, Shapiro D, Mirochnick M for the IMPAACT 1032 Team. Early Postpartum Pharmacokinetics (PK) of Lopinavir (LPV) when Initiated Intrapartum in Thai Women: a substudy of the IMPAACT P1032 Trial. (Abstract #T-151, poster #630) 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008), February 3-6, 2008, Boston, MA.
81. Crain M, Chernoff M, Oleske J, Brogly S, Malee K, Borum P, Meyer WA III, Mitchell W, Moye J, Ford-Chatterton H, Tappenden J, Djokic D, Van Dyke R, Seage G and the P219/219C iDACS 616 Study Team. Possible Mitochondrial Dysfunction in a Large U.S. Cohort of HIV-Infected Children. (Abstract # , poster #R-152) 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008), February 3-6, 2008, Boston, MA.
82. L.M. Mofenson, P. Williams, M.T. Brady, R.B. Van Dyke, W.M. Dankner, J.M. Oleske. Trends in Mortality in HIV-Infected Children in the United States - 1994-2006. XVII International AIDS Conference, Mexico City, Mexico, 3-8 August 2008.
83. Van Dyke R, Patel K, Read J, Chernoff M, Mofenson L, Siberry G, Burchett S, Mendez H, Rodriguez Z, Seage G, and the Pediatric HIV/AIDS Cohort Study. Antiretroviral Therapy Among Children with Perinatally-Acquired HIV Infection: Temporal Changes in Antiretroviral Therapy and Virologic and Immunologic Outcomes in the Pediatric HIV/AIDS Cohort Study Adolescent Master Protocol. (Abstract 901) 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009), Montreal, Canada, February 8-11, 2009.

84. Siberry G, Patel K, Burchett S, Bacon M, Hazra R, Read J, Seage G, Mofenson L, Chernoff M, Van Dyke R, for the Pediatric HIV/AIDS Cohort Study. Discontinuation of Antiretroviral Therapy (ART) among Children with Perinatally-Acquired HIV infection. (Abstract #919) 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009), Montreal, Canada, February 8-11, 2009.
85. Miller T, Jacobson D, Mendez A, Hazra R, Geffner M, Siberry G, Borkowsky W, Patel K, McFarland E, and Van Dyke R for the Pediatric HIV/AIDS Cohort Study. Biomarkers of Vascular Dysfunction in HIV-Infected Children With and Without Hyperlipidemia. (Abstract #917) 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009), Montreal, Canada, February 8-11, 2009.
86. Jacobson D, DiMeglio L, Hazra R, Geffner M, Van Dyke R, Borkowsky W, Patel K, McFarland E, Chen J and L. Miller T for the Pediatric HIV/AIDS Cohort Study. Clinical Determinants of Bone Mineral Density (BMD) in Perinatally HIV-Infected Children. (Abstract #911) 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009), Montreal, Canada, February 8-11, 2009.
87. Van Dyke R, Jourdain G, Shapiro D, Ngo-Giang-Huong N, Frenkel L, Britto P, Roongpisuthipong A, Yuthavisuthi P, Prommas S, Puthanakit T, and the IMPAACT P1032 Protocol Team. A Phase II Study of the Incidence of Nevirapine Resistance Mutations (NR) in HIV-Infected Thai Women Receiving a Single Intrapartum (IP) Dose of NVP (SDNVP) Followed by a Postpartum (PP) Tail of ZDV/ddl or ZDV/ddl/LPV/r (PACTG/IMPAACT P1032) (paper 95aLB). 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009), Montreal, Canada, February 8-11, 2009.
88. Williams P,L, Van Dyke R, Seage GR III, Griner R, Jacobson DL,, Brogly S, Tassiopoulos K, Huo Y, Hazra R, Siberry G, Read JS, Mofenson L, Rich K for the PHACS Team. A Trigger-Based Design for Evaluating the Safety of in utero Antiretroviral Exposure in Uninfected Children Born to HIV-Infected Mothers. 13th International Workshop on HIV Observational Databases, Lisbon, Portugal, March 26-28, 2009.
89. Geffner, M, Jacobson DL, Miller TC, MD, DiMeglio L, Hazra R, Siberry G, Borkowsky W, Patel K, McFarland E, Chen J, Worrell C, Van Dyke R. Insulin Resistance in Adolescents with Perinatally-Acquired HIV Infection (Abstract #: 751886) 2009 Pediatric Academic Societies' Annual Meeting in Baltimore, Maryland, May 2 - 5.
90. Usitalo A, Allison S, Leister E, Malee K, Mellins C, Paul M, Seage III G, Smith R, Tassiopoulos K, Van Dyke R for the Pediatric HIV/AIDS Cohort Study (PHACS). Relationship between viral load and behavioral measures of medication adherence among children and adolescents with HIV infection. To be presented at the 2010 Pediatric Academic Societies' Annual Meeting, Vancouver, BC, Canada.
91. Jacobson D, Patel K, Van Dyke R, Hazra R, Geffner M, DiMeglio L, Siminski S, Miller T. Differences in Body Fat Distribution in HIV-infected versus HIV-infected Children. To be presented at the *17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)*, San Francisco, CA. 2010.
92. Patel K, Mittleman MA, Colan S, Van Dyke RB, Oleske JM, Patel K, Seage GR. Predictors of Cardiac Dysfunction among Children and Adolescents Perinatally-Infected with HIV-1. Submitted to XIX International AIDS Conference, Vienna, 2010.

Selected Invited Lectureships and Symposia:

- "Transfusion Associated CMV", American Society of Clinical Pathologists, National Meeting, New Orleans, LA. 1985
- "Aerosol Use of Ribavirin for RSV and Influenza" 2nd Annual Clinical Virology Symposium Clearwater, Florida. 1986
- "Pathogenesis, Diagnosis, and Treatment of RSV Infections" Pediatric Grand Rounds University of Pennsylvania at Hershey Hershey, Pennsylvania. 1988

- "The Afebrile Pneumonia Syndrome of Infancy" American Academy of Pediatrics, Pediatrics Update Tape. 1989
- "The Immunology of HIV and Pediatric HIV Infections" III Congreso Centroamericano de Neuropsicologia, Tegucigalpa, Honduras. 1991
- "Pediatric AIDS". American Academy of Pediatrics, 60th Annual Meeting, New Orleans, LA, Oct. 26-31, 1991.
- "Helicobacter Pylori", "Infectious Gastroenteritis in Childhood", "Viral Hepatitis in Childhood", "Epidemiology of AIDS", and "Enteric Infections in Children With AIDS". XIV Congreso Centroamericano Y Panama De Gastroenterology, Guatemala City, Guatemala, November 13-16, 1991.
- "Lymphocyte Subsets in HIV-Infected Children and Uninfected Children Born to HIV-Infected Mothers" NIH/CDC conference on the Measurement and Use of CD4+ and Other Lymphocyte Immunophenotypic Markers in Pediatric HIV Infection. Washington, D.C. October 22-23, 1992
- "Opportunistic Infections in Pediatric HIV Disease" New York Academy of Sciences Washington, D.C. November 18-21, 1992.
- "Workshop on Mycobacterial Infections in Children With HIV Infection". Pediatric AIDS Foundation, September, 1993.
- "New Directions in HIV Therapy and Prevention of Transmission" Infectious Diseases Society of America/ICAAC Joint Session. New Orleans, LA, October 18, 1993.
- "AIDS Update". National Hemophilia Foundation, Louisiana Chapter, Baton Rouge, LA September 24, 1994.
- "HIV Update" Louisiana Perinatal Association of Louisiana Association of Perinatal Nurses Meeting, New Orleans, LA October 28, 1994.
- "HIV: 1994" Louisiana Chapter of the American Academy of Pediatrics, Pediatric Potpourri VII. New Orleans, LA December 2, 1994.
- "TB Manejo de la Recurrencias", Enfermedades Infecciosas Incluyendo Terapla Antiviral del SIDA", "Manjo Contemporaneo del Herpes". Actualizacion en Pediatria, 2nd Curso Internacional. Sociedad Panamena de Pediatria and Universidad Nacional de Panema, Panema City, Panema. Nov. 14-16, 1996.
- "Perinatal HIV Transmission". AIDS: The Second Decade" Children's Hospital and Health Center, San Diego, CA. March 15, 1997.
- "Pediatric HIV: Making Progress in Prevention and Therapy". The Child With Special Needs. Contemporary Forums. New Orleans, LA, April 28-30, 1997.
- "Advances in Prevention of Respirator Syncytial Virus Infections" American Academy of Pediatrics, New Orleans, Nov. 3, 1997.
- "Prevention and Treatment of Opportunistic Infections in Pediatric HIV Disease." The Second National Congress on HIV and AIDS" Bucharest, Romania. October 20-23, 1998.
- "Adherence: Helping Patients Manage Complex Medical Regimens". The Fourteenth Annual Rocky Mountain Regional Conference on HIV Disease. Denver, Colorado, Feb. 19-20, 1999.
- "Advances in Prevention of Perinatal HIV Infection". Pediatric Grand Rounds, University of Colorado, Denver, Colorado, Feb. 20, 1999.
- "Preventing Perinatal HIV". Annual Meeting, Louisiana Perinatal/Maternal Child Health Foundation. Baton Rough, Louisiana. March 25-26, 1999.

Invited speaker, IX Panamerican Congress on Infectious Diseases, Guatemala City, Guatemala, May 3-7, 1999.

“Management of the HIV-Infected Child”. Journee Scientifique Nationale, Societe Haitienne de Pediatrie, Hopital Saiant-Damien. June 11, 1999, Port-au-Prince, Haiti.

“Mother-to-Child Transmission of HIV in the Pre-HAART Era: The Role of Drugs of Abuse” Presented at NIDA symposium on Mother-to-Child Transmission of HIV and Drugs of Abuse: Post-HAART Era ,Rockville, Maryland, September 26-27, 2009.

Signature

Date

March 10, 2010